About Marcus Muehlbauer
Marcus Mühlbauer, M.D., PhD, received his initial clinical and research training at the University of Regensburg, Germany. In 2006, he became interested in researching the role of the microbiome in inflammatory bowel disease; specifically colitis-associated colon cancer. He joined the laboratory of Christian Jobin, PhD, at the University of North Carolina in Chapel Hill (UNC) and graduated from UNC’s gastroenterology fellowship program in 2014 specializing in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Mühlbauer joined UF in June 2015 and became the director of the Inflammatory Bowel and Celiac Disease Program in January 2019. He also serves as director of the University of Florida Fecal Microbiota Transplant Program. Dr. Mühlbauer’s primary focus is achieving the highest quality of life for patients suffering from inflammatory bowel disease.
Internal MedicineAmerican Board of Internal Medicine
- Crohn disease
- Pseudomembranous colitis
- Ulcerative colitis
Dr. Mühlbauer’s overarching goal is to provide the best care available for patients suffering from inflammatory bowel disease (Crohn’s disease and ulcerative colitis), or IBD. Besides commercially available treatment options, the University of Florida participates in a variety of new and exciting clinical trials our patients can participate in. Dr. Mühlbauer also works very closely with UF’s cutting edge research labs to find a cure for IBD. Patients can support the development of potentially new treatments by allowing us to collect information from them in a clinical setting and provide extremely small tissue samples during their normally scheduled clinical procedures. Dr. Mühlbauer believes improving the education of physicians in training is of the utmost importance. At UF, we take pride in educating the next generation of IBD physicians so that they can provide the best care to patients suffering from Crohn’s disease or ulcerative colitis in the future.